Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
13/08/2025
Nvidia continues to decline, falling more than 0.7% now.
Latest
3 m ago
Langbo Technology: Net profit in the first half of 2025 increased by 60.18% year-on-year.
3 m ago
Ruixin Technology: The controlling shareholder of the company has changed to Huangshan State-owned Assets Supervision and Administration Commission.
3 m ago
Eon Group warns: Germany may fall behind in energy transition.
5 m ago
According to a report released by Minsheng Securities on August 13, Changan Automobile (000625.SZ) has been given a recommended rating. The reasons for the rating mainly include: 1) Initial increase in holding to help the company become stronger and better; 2) The establishment of the new Changan Automobile Group deepens resource integration and synergy; 3) Avita and Shenlan accelerate the transformation of new energy. (Daily Economic News)
5 m ago
According to the AI Express of Every Economy, Huaxin Securities issued a research report on August 13, giving Ganli Pharmaceutical (603087.SH) a buy rating. The main reasons for the rating include: 1) impressive performance in the first half of 2025, with both volume and price rising domestically, and high growth in overseas markets; 2) orderly advancement of innovative product pipeline, with core products entering phase III clinical trials. (Daily Economic News)
See all latest